9-ethyl-4,6-dioxo-10-propyl-4H,6H,9H-chromeno[7,6-b]pyridine-2,8-dicarboxylic acid

• ChemBase编号: 597
• 分子式: C19H17NO7
• 平均质量: 371.34078
• 单一同位素质量: 371.10050189
• SMILES: o1c2c(c3n(CC)c(cc(=O)c3cc2c(=O)cc1C(=O)O)C(=O)O)CCC
• Canonical SMILES: CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(=O)O)C(=O)O
• InChI: InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)
• InChIKey: RQTOOFIXOKYGAN-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 9-ethyl-4,6-dioxo-10-propyl-4H,6H,9H-chromeno[7,6-b]pyridine-2,8-dicarboxylic acid
• IUPAC传统名: nedocromil
• 商标名: Alocril; Nedocromil [USAN:BAN:INN]; Nedocromilo [Spanish]; Nedocromilum [Latin]; Tilade
• 别名: Nedocromil

登记号

• CAS号: 69049-73-6
• PubChem SID: 160964060; 46507587
• PubChem CID: 50294

理论计算性质

JChem

• Acid pKa: 2.2765472
• 质子受体: 8
• 质子供体: 2
• LogD (pH = 5.5): -2.950341
• LogD (pH = 7.4): -4.4912534
• Log P: 2.4967167
• 摩尔折射率: 98.086 cm^3
• 极化性: 35.33119 Å^3
• 极化表面积: 121.21 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.18
• LOG S: -3.91
• 溶解度: 4.59e-02 g/l

分子性质

理化性质

• 溶解度: 145 mg/L
• 疏水性(logP): 2.6

详细说明

DrugBank - DB00716

• Drug Groups: approved
• Description: A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. [PubChem]
• Indication: For the treatment of mild to moderate asthma
• Pharmacology: Nedocromil is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness.
• Toxicity: Side effects include headache, nasal congestion, ocular burning, irritation and stinging, unpleasant taste, cough, difficulty breathing, noisy breathing, shortness of breath, tightness in chest, wheezing, conjunctivitis, blurred vision, change in color vision, difficulty seeing at night, increased sensitivity of eyes to sunlight.
• Affected Organisms: Humans and other mammals
• Biotransformation: Nedocromil is not metabolized after IV administration and is excreted unchanged.
• Absorption: Low
• Half Life: ~3.3 hours
• Protein Binding: approximately 89% protein bound in human plasma over a concentration range of 0.5 to 50 µg/mL
• Elimination: It is not metabolized and is eliminated primarily unchanged in urine (70%) and feces (30%).
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com